Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Barbara Gayle Duncan currently holds 90,000 shares of INTERCEPT PHARMACEUTICALS INC (ICPT), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Barbara Gayle Duncan has been a net seller of ICPT stock. They have purchased $75.0K and sold $7.4M worth of shares.
Barbara Gayle Duncan's most recent insider trade was on Dec 12, 2024, when they sold 90,000 shares at $0.00 per share.
Barbara Gayle Duncan serves as Executive at INTERCEPT PHARMACEUTICALS INC (ICPT). They have executed 110 insider transactions totaling $7.5M over their tenure at the company.
Barbara Gayle Duncan holds the position of Executive at INTERCEPT PHARMACEUTICALS INC, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 13 years and currently hold a stake valued at $0.
Barbara Gayle Duncan has shown a selling trading pattern, with $75.0K in total purchases and $7.4M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Barbara Gayle Duncan was on Aug 17, 2020, when they sold $339.2K worth of IMMU shares. This transaction involved 20,000 shares at $16.96 per share.
Barbara Gayle Duncan currently owns 90,000 shares of INTERCEPT PHARMACEUTICALS INC (ICPT), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Barbara Gayle Duncan's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Barbara Gayle Duncan has 110 Form 4 filings on record as an insider at INTERCEPT PHARMACEUTICALS INC.
Set alerts for Barbara Gayle Duncan and 40,000+ other insiders.